RBC Capital Downgrades Marinus Pharma to Sector Perform, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams downgraded Marinus Pharma (MRNS) from Outperform to Sector Perform and significantly reduced the price target from $24 to $3.
April 15, 2024 | 6:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Marinus Pharma was downgraded by RBC Capital from Outperform to Sector Perform, with a drastic reduction in price target from $24 to $3.
The downgrade from Outperform to Sector Perform by a major analyst, along with a significant reduction in price target, suggests a bearish outlook on MRNS's short-term performance. This could lead to a decrease in investor confidence and potentially lower stock prices in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100